Phosphodiesterase type 5 inhibitors and kidney disease

Baris Afsar, Alberto Ortiz, Adrian Covic, Abduzhappar Gaipov, Tarik Esen, David Goldsmith, Mehmet Kanbay

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

Chronic kidney disease (CKD) represents a worldwide health problem. Traditionally, the nephroprotective treatment for CKD aims to slow progression to end-stage renal disease and includes dietary protein restriction, correction of metabolic acidosis, and renin–angiotensin system blockers. However, current standard therapeutic options may not be enough for preventing CKD progression in a subset of patients making necessary to develop novel therapeutic options to further slow renal function loss. Phosphodiesterase type 5 (PDE5) inhibitors represent a class of drugs traditionally used to treat erectile dysfunction and pulmonary hypertension. However, recent evidence suggests that PDE5 inhibitors may have additional therapeutic effects, such as cardioprotection and cerebrovascular protection. In the current review, we summarize PDE5 inhibitors’ utility in disease states and clinical conditions related to kidney disease such as systemic hypertension and acute and chronic kidney injury and discuss the mechanisms explaining possible kidney protective roles of PDE5 inhibitors. A recently completed phase 2 trials demonstrated that the long-acting PDE5 inhibitor PF-00489791 decreased albuminuria in patients with overt diabetic nephropathy when added on top of renin–angiotensin system blockade.

Original languageEnglish (US)
Pages (from-to)1521-1528
Number of pages8
JournalInternational Urology and Nephrology
Volume47
Issue number9
DOIs
StatePublished - Sep 26 2015

Fingerprint

Phosphodiesterase 5 Inhibitors
Kidney Diseases
Chronic Renal Insufficiency
Kidney
Albuminuria
Dietary Proteins
Diabetic Nephropathies
Therapeutic Uses
Erectile Dysfunction
Acidosis
Acute Kidney Injury
Pulmonary Hypertension
Chronic Kidney Failure
Disease Progression
Therapeutics
Hypertension
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Nephrology
  • Urology

Cite this

Afsar, B., Ortiz, A., Covic, A., Gaipov, A., Esen, T., Goldsmith, D., & Kanbay, M. (2015). Phosphodiesterase type 5 inhibitors and kidney disease. International Urology and Nephrology, 47(9), 1521-1528. https://doi.org/10.1007/s11255-015-1071-4

Phosphodiesterase type 5 inhibitors and kidney disease. / Afsar, Baris; Ortiz, Alberto; Covic, Adrian; Gaipov, Abduzhappar; Esen, Tarik; Goldsmith, David; Kanbay, Mehmet.

In: International Urology and Nephrology, Vol. 47, No. 9, 26.09.2015, p. 1521-1528.

Research output: Contribution to journalReview article

Afsar, B, Ortiz, A, Covic, A, Gaipov, A, Esen, T, Goldsmith, D & Kanbay, M 2015, 'Phosphodiesterase type 5 inhibitors and kidney disease', International Urology and Nephrology, vol. 47, no. 9, pp. 1521-1528. https://doi.org/10.1007/s11255-015-1071-4
Afsar, Baris ; Ortiz, Alberto ; Covic, Adrian ; Gaipov, Abduzhappar ; Esen, Tarik ; Goldsmith, David ; Kanbay, Mehmet. / Phosphodiesterase type 5 inhibitors and kidney disease. In: International Urology and Nephrology. 2015 ; Vol. 47, No. 9. pp. 1521-1528.
@article{8ffd55b439574eb88f546852216287a2,
title = "Phosphodiesterase type 5 inhibitors and kidney disease",
abstract = "Chronic kidney disease (CKD) represents a worldwide health problem. Traditionally, the nephroprotective treatment for CKD aims to slow progression to end-stage renal disease and includes dietary protein restriction, correction of metabolic acidosis, and renin–angiotensin system blockers. However, current standard therapeutic options may not be enough for preventing CKD progression in a subset of patients making necessary to develop novel therapeutic options to further slow renal function loss. Phosphodiesterase type 5 (PDE5) inhibitors represent a class of drugs traditionally used to treat erectile dysfunction and pulmonary hypertension. However, recent evidence suggests that PDE5 inhibitors may have additional therapeutic effects, such as cardioprotection and cerebrovascular protection. In the current review, we summarize PDE5 inhibitors’ utility in disease states and clinical conditions related to kidney disease such as systemic hypertension and acute and chronic kidney injury and discuss the mechanisms explaining possible kidney protective roles of PDE5 inhibitors. A recently completed phase 2 trials demonstrated that the long-acting PDE5 inhibitor PF-00489791 decreased albuminuria in patients with overt diabetic nephropathy when added on top of renin–angiotensin system blockade.",
author = "Baris Afsar and Alberto Ortiz and Adrian Covic and Abduzhappar Gaipov and Tarik Esen and David Goldsmith and Mehmet Kanbay",
year = "2015",
month = "9",
day = "26",
doi = "10.1007/s11255-015-1071-4",
language = "English (US)",
volume = "47",
pages = "1521--1528",
journal = "International Urology and Nephrology",
issn = "0301-1623",
publisher = "Springer Netherlands",
number = "9",

}

TY - JOUR

T1 - Phosphodiesterase type 5 inhibitors and kidney disease

AU - Afsar, Baris

AU - Ortiz, Alberto

AU - Covic, Adrian

AU - Gaipov, Abduzhappar

AU - Esen, Tarik

AU - Goldsmith, David

AU - Kanbay, Mehmet

PY - 2015/9/26

Y1 - 2015/9/26

N2 - Chronic kidney disease (CKD) represents a worldwide health problem. Traditionally, the nephroprotective treatment for CKD aims to slow progression to end-stage renal disease and includes dietary protein restriction, correction of metabolic acidosis, and renin–angiotensin system blockers. However, current standard therapeutic options may not be enough for preventing CKD progression in a subset of patients making necessary to develop novel therapeutic options to further slow renal function loss. Phosphodiesterase type 5 (PDE5) inhibitors represent a class of drugs traditionally used to treat erectile dysfunction and pulmonary hypertension. However, recent evidence suggests that PDE5 inhibitors may have additional therapeutic effects, such as cardioprotection and cerebrovascular protection. In the current review, we summarize PDE5 inhibitors’ utility in disease states and clinical conditions related to kidney disease such as systemic hypertension and acute and chronic kidney injury and discuss the mechanisms explaining possible kidney protective roles of PDE5 inhibitors. A recently completed phase 2 trials demonstrated that the long-acting PDE5 inhibitor PF-00489791 decreased albuminuria in patients with overt diabetic nephropathy when added on top of renin–angiotensin system blockade.

AB - Chronic kidney disease (CKD) represents a worldwide health problem. Traditionally, the nephroprotective treatment for CKD aims to slow progression to end-stage renal disease and includes dietary protein restriction, correction of metabolic acidosis, and renin–angiotensin system blockers. However, current standard therapeutic options may not be enough for preventing CKD progression in a subset of patients making necessary to develop novel therapeutic options to further slow renal function loss. Phosphodiesterase type 5 (PDE5) inhibitors represent a class of drugs traditionally used to treat erectile dysfunction and pulmonary hypertension. However, recent evidence suggests that PDE5 inhibitors may have additional therapeutic effects, such as cardioprotection and cerebrovascular protection. In the current review, we summarize PDE5 inhibitors’ utility in disease states and clinical conditions related to kidney disease such as systemic hypertension and acute and chronic kidney injury and discuss the mechanisms explaining possible kidney protective roles of PDE5 inhibitors. A recently completed phase 2 trials demonstrated that the long-acting PDE5 inhibitor PF-00489791 decreased albuminuria in patients with overt diabetic nephropathy when added on top of renin–angiotensin system blockade.

UR - http://www.scopus.com/inward/record.url?scp=84940440236&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940440236&partnerID=8YFLogxK

U2 - 10.1007/s11255-015-1071-4

DO - 10.1007/s11255-015-1071-4

M3 - Review article

VL - 47

SP - 1521

EP - 1528

JO - International Urology and Nephrology

JF - International Urology and Nephrology

SN - 0301-1623

IS - 9

ER -